ERBB2 and adenocarcinoma: The prognostic impact of HER2-positive NSCLC is still equivocal, although HER2 overexpression/amplification seems to be associated with reduced disease-free survival and poor outcomes, especially for adenocarcinomas, early-stage NSCLC, and small-cell lung cancer (SCLC) [45].